Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Investor profile

OrbiMed

Private equity / VC · Founded 1989 · Active in 2026

OrbiMed is a private equity / vc based in USA, founded in 1989. The page below shows 113 Power Law outcomes from OrbiMed's portfolio — 76 unicorns ($1B+ valuation) and 8 additional thoroughbreds (companies that crossed $100M+ in revenue without yet reaching $1B+ valuation).

Outcomes are concentrated in Biotech & Life Sciences · Health Tech & Medtech; top portfolio geographies are USA · China · Canada. OrbiMed ranks #98 in Global in the 2026 Dealroom Power Law Investor Ranking by cross-stage outcomes.

113 Power Law outcomes Power Law Ranking #98 · Global · 113 Power Law outcomes · Active 2026
Unicorns ↑ 49% 5y
76
Decacorns ↑ 75% 5y
7
Thoroughbreds ↑ 45% 5y
44
01 · Exits

Sequoia’s biggest exits.

Sequoia portfolio companies worth $1B+ that have IPO’d or been acquired. Each shows its valuation at exit and, in grey, its current value if still public.

IPO · 1999
Entered SeedNow $5.2T
IPO · 2004
Entered Series ANow $4.6T
IPO · 1980
Now $4.5T
IPO · 2014
Entered Series B+Now $306B
$214B IPO · 2021
Entered Series B+Now $20.1B
IPO · 2012
Entered Series ANow $207B
$82.0B IPO · 2019
Now $153B
IPO · 2012
Entered Series B+Now $103B
$95.0B IPO · 2020
Entered SeedNow $69.1B
$93.9B IPO · 2020
Entered Series B+Now $58.4B
$24.0B IPO · 2018
Entered Series B+Now $73.3B
$39.0B IPO · 2020
Entered Series ANow $67.6B
$32.0B IPO · 2021
Entered Series B+Now $67.5B
$41.5B IPO · 2021
Entered SeedNow $64.4B
$60.0B IPO · 2021
Entered Series B+Now $28.0B
$55.5B IPO · 2026
Entered Series B+Now $55.5B
$52.8B IPO · 2018
Entered Series ANow $49.6B
IPO · 2013
Now $45.0B
IPO · 2015
Entered Series B+Now $39.4B
IPO · 2002
Entered SeedNow $39.1B
$32.0B acquisition · 2025
Entered Seed
$12.0B IPO · 2021
Entered Series B+Now $29.5B
IPO · 2014
Entered Series B+Now $28.6B
IPO · 2015
Entered Series ANow $28.2B
03 · Portfolio analysis

The 113 OrbiMed Power Law outcomes ($100M+ revenue or $1B+ valuation).

Snapshot of where the outcomes are concentrated by country, sector, and stage entered.

By countryCount
  1. USA88
  2. China9
  3. Canada5
  4. UK3
  5. Denmark2
  6. Switzerland2
  7. France1
  8. Netherlands1
  9. India1
  10. Belgium1
By sectorCount
  1. Biotech & Life Sciences109
  2. Health Tech & Medtech4
By stage enteredCount
  1. Series B+62
  2. Series A24
  3. Seed1
Estimated holdings

OrbiMed’s biggest current holdings.

An estimate of OrbiMed’s largest live positions — disclosed shareholding × Dealroom’s latest valuation — across 1 companies where OrbiMed is a named shareholder, worth about $16M in estimated equity value.

#CompanyEst. stakeValuationEst. value
  1. 1 Miaoshou DoctorHealth · Unicorn 0.7% $2.3B $16M

Estimated value = OrbiMed’s disclosed ownership % × Dealroom’s latest company valuation; direct named stakes only, exited positions excluded. Figures are indicative, not reported marks. See the underlying cap tables on Dealroom →

OrbiMed’s biggest exits.

OrbiMed portfolio companies worth $1B+ that have IPO’d or been acquired. Each shows its valuation at exit and, in grey, its current value if still public.

IPO · 2014
Entered Series B+Now $46.2B
IPO · 2015
Entered Series B+Now $28.2B
$1.6B IPO · 2018
Entered Series B+Now $16.4B
IPO · 2015
Entered Series B+Now $15.6B
IPO · 2007
Entered Series B+Now $11.2B
IPO · 2013
Entered Series B+Now $10.9B
$163M IPO · 2017
Entered Series ANow $10.0B
IPO · 2004
Entered Series B+Now $9.8B
IPO · 2014
Entered Series ANow $8.0B
$7.6B IPO · 2025
Entered Series B+Now $4.0B
$7.0B acquisition · 2016
Entered Series A
IPO · 2015
Entered Series B+Now $6.9B
$443M IPO · 2017
Entered Series ANow $5.8B
$430M IPO · 2021
Entered Series B+Now $5.1B
$1.1B IPO · 2023
Entered Series B+Now $5.1B
$350M IPO · 2018
Now $5.0B
IPO · 2015
Entered Series ANow $4.5B
IPO · 2014
Entered Series B+Now $4.2B
$4.1B IPO · 2023
Entered Series B+Now $3.7B
$3.7B IPO · 2019
Now $2.1B
$386M IPO · 2018
Entered Series B+Now $3.7B
$300M IPO · 2021
Entered Series B+Now $3.3B
$750M IPO · 2019
Entered Series ANow $3.3B
$1.8B IPO · 2025
Entered Series B+Now $3.2B

+44 more $1B+ exits on the full Dealroom profile.

04 · Portfolio market map

OrbiMed's 113 Power Law outcomes.

Stage entered
Outcome tier
Region
Group by
113 of 113 Power Law outcomes
05 · Power Law comparison

How does OrbiMed stack up?

OrbiMed in orange, your selection in blue and other colours. Pick from the global roster of 609 peer investors — scope by startup location or hit "Find similar shapes" to auto-pick the three closest. The funnel matrix mirrors the spider chart on the ranking page; the line chart shows each firm's share of unicorns minted in the selected startup location — peaks reveal vintage years.

Compare against

Share of new unicorns per year

% of global unicorns minted that year, year by year · hover the chart to see which unicorns
Performance window All-time → 2026

Stage focus

Companies by selected outcome stage

Sector focus

Companies per investor across the 10 highest-volume sectors

Beyond Unicorns — how the portfolio compounds

% of each investor's unicorn portfolio that later crossed $10B, $25B and $50B. Pick a sort tier and entry stage.
Sort by
Entry stage
Source: Dealroom Power Law dataset. Investors shown are the 2026 Power Law top 35 by combined entry-to-outcome score, drawn from the overview and locations_data sheets. Funnel-matrix axes rescale per-axis using the maximum among the currently selected investors, so the polygons always fill the chart for shape comparison.
06 · Portfolio founders

Where Sequoia's portfolio founders come from — and where they studied.

53 founders across the 113 Power Law outcomes — split by country of origin, university attended, and the company they worked at before founding. Aarhus University and Stemcentrx are the deepest single pipelines.

LocationCount
United States23
United Kingdom10
Belgium4
Denmark3
China2
Singapore2
Germany1
Netherlands1
Iran1
View on app →
UniversityCount
Aarhus University3
Stanford University3
University of Bristol2
Aston University2
UCLA2
Harvard University2
Washington University in St. Louis2
Gdański Uniwersytet Medyczny1
Vlerick Business School1
Ghent University1
+19 more →
Origin companyCount
Stemcentrx3
Aiolos Bio3
Five Prime Therapeutics2
Ablynx1
Natera1
Turnstone Biologics1
Nektar Therapeutics1
Immunocore1
RayzeBio1
Avidity Biosciences1
+12 more →
Origin = country a founder is born in or grew up in (founders may have multiple origins; counts include all entries). University = highest-listed degree. Origin company = a previous employer where the founder was tagged before starting their current company.

Market sentiment

What the market is saying about OrbiMed

An AI-synthesized read of the highest-engagement posts about OrbiMed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

In the news

Latest news about OrbiMed

Recent press, funding announcements, and portfolio moves mentioning OrbiMed — pulled live from Dealroom's news feed.

See all news

Want the full picture on OrbiMed?

The Dealroom platform tracks every round, every co-investor, and every portfolio company in real time — across 25,000+ investors and 3M+ companies globally.